Atrium Therapeutics, Inc. (RNA) earnings
Quarterly results of Atrium Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 4 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Atrium Therapeutics, Inc. reported revenue of $3M and a net loss of $20.2M.
Diluted earnings per share were -$1.18.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $3M | - | -$20.2M | -$1.18 |
| Q1 FY2026 | $19.6M | - | -$16.6M | -$0.97 |
| Q2 FY2026 | $3.8M | - | -$12.9M | -$0.75 |
| Q1 FY2026 | $1.6M | - | -$7.4M | -$0.44 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
What were Atrium Therapeutics, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Atrium Therapeutics, Inc. reported revenue of $3M and a net loss of $20.2M. The figures come from its filing with the SEC.
Get an email when RNA reports
Follow RNA and we email you its next results the day they are filed, with the numbers explained.